Integrating Systemic Therapies into the Multimodality Treatment of Resectable Colorectal Liver Metastases

Colorectal carcinoma (CRC) is one of the most common cancers worldwide. A considerable proportion of CRC patients may present with metastatic disease either at upfront presentation (synchronous with the primary) or following diagnosis and treatment of the primary tumor (metachronous). Management of...

Full description

Saved in:
Bibliographic Details
Published in:Gastroenterology research and practice 2018-01, Vol.2018 (2018), p.1-4
Main Authors: Abdel-Rahman, Omar, Cheung, Winson Y.
Format: Article
Language:English
Subjects:
Antimitotic agents
Antineoplastic agents
Biology
Cancer therapies
Care and treatment
Chemotherapy
Colorectal cancer
Decision making
Development and progression
Forecasts and trends
Gastroenterology
Homeopathy
Liver
Liver cancer
Materia medica and therapeutics
Metastasis
Oncology
Patients
Review
Strategic planning (Business)
Surgery
Systematic review
Therapeutics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Colorectal carcinoma (CRC) is one of the most common cancers worldwide. A considerable proportion of CRC patients may present with metastatic disease either at upfront presentation (synchronous with the primary) or following diagnosis and treatment of the primary tumor (metachronous). Management of CRC liver metastases is a challenging endeavor which frequently necessitates proper assessment of patient- and disease-related factors. There is an opportunity within the management of CRC liver metastases to incorporate multiple treatment modalities (including surgery, other locoregional treatments, and systemic therapy). The current review aims to provide an updated overview on the optimal management strategy for CRC patients with liver metastases with a specific focus on the integration of systemic and/or locoregional treatments among patients with resectable or potentially resectable disease.
ISSN:1687-6121
1687-630X
DOI:10.1155/2018/4326082